Clinical Trial Finds Enzyme Blend Eases Joint Pain in 92% of Dogs with Arthritis
核心洞察
A randomized, double-blind, placebo-controlled trial found Exclzyme Pet (搜索) improved joint health in 92% of dogs with diagnosed arthritis (搜索) over 30 days.
Treated dogs showed a 56% reduction in pain, a 52% drop in lameness, and a 49% improvement in joint mobility compared with baseline.
The US pet supplement market was valued at $895.91 million in 2023 and is forecast to reach $1.475 billion by 2032, with joint support among top sellers.
A newly published randomized, double-blind, placebo-controlled trial has demonstrated that Exclzyme Pet (搜索), a systemic enzyme blend developed by Specialty Enzymes & Probiotics (搜索), delivered measurable joint health improvements in 92% of dogs studied. The findings provide rare species-specific clinical evidence in a pet supplement category that has historically relied on human data or anecdotal reports.
The 30-day trial enrolled 24 dogs with diagnosed arthritis (搜索), randomized to receive either 1 g of Exclzyme Pet (搜索) twice daily or a placebo. Researchers assessed multiple endpoints including pain scores, lameness, joint mobility, and radiological markers.
Significant Improvements Across All Measured Endpoints
Compared with baseline, treated dogs demonstrated a 56% reduction in pain, a 52% drop in lameness, a 49% improvement in joint mobility issues, and a 46% reduction in weight-bearing problems. Additionally, researchers observed a 58% increase in willingness to bear weight on the opposite limb, suggesting meaningful functional recovery.
Reshma Rathi, Vice President of Specialty Enzymes & Probiotics (搜索), emphasized the significance of conducting species-specific research. "With joint issues affecting such a large percentage of companion animals, these findings are highly relevant for the pet supplement industry," Rathi said. She noted that the ingredient category has often relied on borrowed human data or anecdotal evidence rather than dedicated clinical trials in the target species.
Market Context and Unmet Need
The results arrive as the pet joint health segment experiences substantial commercial growth. The US pet supplement market was valued at $895.91 million in 2023 and is projected to reach $1.475 billion by 2032, growing at a compound annual growth rate of 5.7%. Joint support products consistently rank among the category's top sellers.
Industry estimates suggest that up to 52% of dogs and cats experience joint issues during their lifetime, while approximately 36% of pet owners already purchase joint supplements for their animals. This substantial disease burden underscores the relevance of clinically validated interventions.
Product Availability and Quality Standards
Exclzyme Pet (搜索) is available in capsule, packet, and powder formats, offering formulators flexibility across product positioning and consumer channels. The product is manufactured in NSF GMP, FSSC 22000, and ISO-17025 certified facilities and carries vegetarian, gluten-free, halal, and kosher certifications.
Pet owners are deeply invested in their companions' comfort and vitality, and this study positions Exclzyme Pet (搜索) as a clinically supported option in the joint health space. The company described the findings as carrying weight for an ingredient category that has lacked rigorous, species-specific clinical validation.